Polyiclc
Advanced Malignant Solid Tumors
The First Affiliated Hospital of Nanchang UniversityN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
36 Active assets in the Advanced Malignant Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Neratinib Puma Biotechnology, Inc. | Phase 1/2 | B |
TRASTUZUMAB Puma Biotechnology, Inc. | Phase 1/2 | B |
Vinorelbine Puma Biotechnology, Inc. | Phase 1/2 | B |
Capecitabine Puma Biotechnology, Inc. | Phase 1/2 | B |
Trastuzumab Emtansine Puma Biotechnology, Inc. | Phase 1/2 | B |
View all 50 →
Same molecule, other indications
Polyiclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →